文献速递妇科

复发性卵巢癌奥拉帕利维持治疗SOLO2/ENGOT-Ov21试验安慰剂组的不良事件

Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2024-11-12

SOLO2/ENGOT-Ov21试验将295例BRCA1/2突变的铂敏感复发性卵巢癌患者随机分为奥拉帕利维持治疗组(196例)和安慰剂组(99例)。安慰剂组99例中95%报告至少1起不良事件,22%报告至少1起≥3级不良事件,研究者将25%的不良事件归因于安慰剂治疗。

要点

  • 安慰剂组95%的患者报告至少1起不良事件,22%报告至少1起≥3级不良事件。
  • 持续超过100天的≥2级不良事件影响21%的患者,44%的患者经历复发性≥1级不良事件。
  • 研究者将25%的不良事件归因于安慰剂,其中中性粒细胞减少(88%)、恶心(52%)和血小板减少(50%)最常被归因。

核心结论

  • SOLO2/ENGOT-Ov21试验中几乎所有铂敏感复发性卵巢癌安慰剂组患者经历至少1起不良事件,研究者将四分之一的不良事件归因于安慰剂治疗,并据此进行了剂量调整和治疗变更。
  • 需要进一步工作以改进铂敏感复发性卵巢癌维持治疗试验中不良事件的测量和分类。

研究设计与样本

  • SOLO2/ENGOT-Ov21(NCT01874353)随机分配295例BRCA1/2突变的铂敏感复发性卵巢癌患者至奥拉帕利片剂维持治疗组(N=196)或匹配安慰剂组(N=99)。
  • 对安慰剂组患者分析不良事件(CTCAE v4.0)数据,包括类型、分级、发生和缓解时间及研究者归因。

主要发现

  • 99例接受安慰剂的患者共报告788起不良事件,95%报告至少1起不良事件。
  • 22%的患者报告至少1起≥3级不良事件;持续超过100天的≥2级不良事件影响21%的患者;44%的患者经历复发性≥1级不良事件。
  • 研究者将25%的不良事件归因于安慰剂治疗,中性粒细胞减少(88%)、恶心(52%)和血小板减少(50%)最常被归因。
  • 因归因于安慰剂的不良事件,3%的患者剂量减少,19%治疗延迟,2%永久终止治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步工作以改进铂敏感复发性卵巢癌维持治疗试验中不良事件的测量和分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In women with platinum sensitive recurrent ovarian cancer (PSROC) undergoing maintenance treatment, adverse events (AEs) not attributable to the current treatment are not well understood. We used data from SOLO2/ENGOT-Ov21 to evaluate AEs reported in the placebo arm and to explore their longitudinal trajectories. METHODS: SOLO2/ENGOT-Ov21 (NCT01874353) randomly assigned 295 PSROC participants with a BRCA1/2 mutation to maintenance olaparib tablets (N = 196) or matching placebo (N = 99). For those assigned to placebo, we analyzed the AE (CTCAE v4.0) data including type, grade, time of onset and resolution, and attribution by investigator. RESULTS: Amongst 99 participants who received placebo 788 AEs were reported (95 % reporting ≥1 AE). Twenty-two percent of participants reported at least one grade ≥ 3 AE. Grade ≥ 2 AEs that persisted for over 100 days affected 21 % of participants. Recurring grade ≥ 1 AEs were experienced by 44 % of participants. Study investigators attributed 25 % of all AEs to the placebo treatment, with neutropenia (88 %), nausea (52 %) and thrombocytopenia (50 %) most attributed. Three percent of participants had a dose reduction, 19 % had treatment delays, and 2 % had permanent treatment discontinuation, due to AEs attributed to placebo. CONCLUSION: Virtually all PSROC participants in the SOLO2/ENGOT-Ov21 experienced one or more AE whilst on placebo. Furthermore, study investigators attributed one quarter of AEs to be related to placebo therapy and dose alterations and treatment changes were made based on these AE. Further work is needed to improve measurement and categorization of AEs in trials of maintenance therapy in PSROC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Francis KE, Simon S, Gebski V, et al. Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer. Gynecol Oncol. 2024. PMID: 39536691. doi:10.1016/j.ygyno.2024.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。